Effective strategies to identify postmenopausal women at risk for osteoporosis
- PMID: 17999567
Effective strategies to identify postmenopausal women at risk for osteoporosis
Abstract
The early identification of postmenopausal women at risk of fracture, followed by effective therapeutic intervention, can substantially improve patient outcomes. Bone mineral density measurements and comprehensive risk assessment are essential components in deciding when to intervene with osteoporosis pharmacologic treatment. Simple, easy-to-administer risk assessment tools are available to assist the physician in identifying patients in need of further evaluation or treatment and aid in patient counseling. Furthermore, effective pharmacologic treatments are available that have demonstrated reductions in the risk of vertebral and nonvertebral fractures. Some therapies, such as selective estrogen receptor modulators and bisphosphonates, are able to act early in the course of treatment to reduce this risk of vertebral and nonvertebral fractures. The tools to reduce the underrecognition and undertreatment of osteoporosis are readily available. Primary care physicians are in a unique position to use these tools as part of a more proactive approach to fracture prevention in postmenopausal patients.
Similar articles
-
[Therapeutic concepts in the treatment of postmenopausal osteoporosis].Ther Umsch. 1994 Nov;51(11):737-47. Ther Umsch. 1994. PMID: 7839332 German.
-
Recognition of women at risk for fracture and intervention with fast-acting therapies.Int J Fertil Womens Med. 2006 Jul-Aug;51(4):183-90. Int J Fertil Womens Med. 2006. PMID: 17184104 Review.
-
Preventing osteoporosis in symptomatic postmenopausal women.Menopause. 2011 Jan;18(1):109-18. doi: 10.1097/gme.0b013e3181e324a6. Menopause. 2011. PMID: 20661164 Review.
-
[Osteoporosis therapy in general practice. Which measure should be included?].MMW Fortschr Med. 2002 Oct 17;144(42):62. MMW Fortschr Med. 2002. PMID: 12534001 German. No abstract available.
-
Osteodensitometry in healthy postmenopausal women.Prescrire Int. 2008 Apr;17(94):68-72. Prescrire Int. 2008. PMID: 18536138
Cited by
-
Dynamic expression of matrix metalloproteinases 2, 9 and 13 in ovariectomy-induced osteoporosis rats.Exp Ther Med. 2018 Sep;16(3):1807-1813. doi: 10.3892/etm.2018.6356. Epub 2018 Jun 27. Exp Ther Med. 2018. PMID: 30186405 Free PMC article.
-
Effects of JSOG-6 on protection against bone loss in ovariectomized mice through regulation of osteoblast differentiation and osteoclast formation.BMC Complement Altern Med. 2014 Jun 6;14:184. doi: 10.1186/1472-6882-14-184. BMC Complement Altern Med. 2014. PMID: 24903150 Free PMC article.
-
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.Br J Pharmacol. 2008 Nov;155(6):896-905. doi: 10.1038/bjp.2008.305. Epub 2008 Aug 11. Br J Pharmacol. 2008. PMID: 18695641 Free PMC article.
-
Current knowledge and future direction of research on soy isoflavones as a therapeutic agents.Pharmacogn Rev. 2010 Jul;4(8):111-7. doi: 10.4103/0973-7847.70900. Pharmacogn Rev. 2010. PMID: 22228950 Free PMC article.
-
Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone.Acta Pharmacol Sin. 2012 Jan;33(1):66-74. doi: 10.1038/aps.2011.136. Epub 2011 Nov 28. Acta Pharmacol Sin. 2012. PMID: 22120966 Free PMC article.